NASDAQ:BFRA - BIOFRONTERA AG/ADR Stock Price, Forecast & News

BIOFRONTERA AG/ADR trades on the NASDAQ under the ticker symbol "BFRA."

BIOFRONTERA AG/ADR (NASDAQ:BFRA) posted its quarterly earnings results on Monday, April, 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by $0.01. The business had revenue of $7.48 million for the quarter. BIOFRONTERA AG/ADR had a negative return on equity of 34.45% and a negative net margin of 23.35%. View BIOFRONTERA AG/ADR's Earnings History.

BIOFRONTERA AG/ADR is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for BIOFRONTERA AG/ADR.

BIOFRONTERA AG/ADR issued an update on its fourth quarter 2019 Pre-Market earnings guidance on Friday, January, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $13.542-13.542 million, compared to the consensus revenue estimate of $11.45 million.

2 analysts have issued 12 month price objectives for BIOFRONTERA AG/ADR's stock. Their forecasts range from $11.00 to $18.00. On average, they anticipate BIOFRONTERA AG/ADR's stock price to reach $14.50 in the next year. This suggests a possible upside of 28.7% from the stock's current price. View Analyst Price Targets for BIOFRONTERA AG/ADR.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOFRONTERA AG/ADR in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIOFRONTERA AG/ADR.

Media headlines about BFRA stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. BIOFRONTERA AG/ADR earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for BIOFRONTERA AG/ADR.

Some companies that are related to BIOFRONTERA AG/ADR include Odonate Therapeutics (ODT), Applied Therapeutics (APLT), Gossamer Bio (GOSS), Cytokinetics (CYTK), Stoke Therapeutics (STOK), Endonovo Therapeutics (ENDV), Kiniksa Pharmaceuticals (KNSA), Achillion Pharmaceuticals (ACHN), I-Mab (ARQT), Radius Health (RDUS), ImmunoGen (IMGN), Amphastar Pharmaceuticals (AMPH), Homology Medicines (FIXX), Phathom Pharmaceuticals (PHAT) and Dova Pharmaceuticals (DOVA).

Based on aggregate information from My MarketBeat watchlists, some companies that other BIOFRONTERA AG/ADR investors own include GW Pharmaceuticals PLC- (GWPH), Gilead Sciences (GILD), Pattern Energy Group (PEGI), Supernus Pharmaceuticals (SUPN), AbbVie (ABBV), Bank of Nova Scotia (BNS), Energy Transfer LP Unit (ET), Fresenius Medical Care AG & Co. (FMS), GlaxoSmithKline (GSK) and Teva Pharmaceutical Industries (TEVA).

(BFRA) raised $18 million in an IPO on Wednesday, February 14th 2018. The company issued 1,500,000 shares at $11.00-$13.00 per share. Benchmark acted as the underwriter for the IPO and Dawson James Securities and Lake Street Capital Markets were co-managers.

BIOFRONTERA AG/ADR's stock is owned by a number of of institutional and retail investors. Top institutional investors include Sowell Financial Services LLC (0.08%).

BFRA stock was acquired by a variety of institutional investors in the last quarter, including Sowell Financial Services LLC.

Shares of BFRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BFRA stock can currently be purchased for approximately $11.26.

BIOFRONTERA AG/ADR has a market capitalization of $252.50 million and generates $24.93 million in revenue each year. BIOFRONTERA AG/ADR employs 149 workers across the globe.View Additional Information About BIOFRONTERA AG/ADR.

The official website for BIOFRONTERA AG/ADR is http://www.biofrontera.com/.

BIOFRONTERA AG/ADR's mailing address is HEMMELRATHER WEG 201, LEVERKUSEN 2M, D-51377. The company can be reached via phone at 011-49-2148-7600 or via email at [email protected]